{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-Negative+Breast+Cancer&page=2", "query": { "condition": "HER2-Negative Breast Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-Negative+Breast+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T13:22:21.326Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05867251", "title": "Study of AVZO-021 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "HR+/HER2- Breast Cancer", "HR+, HER2-, Advanced Breast Cancer", "CCNE1 Amplification", "Epithelial Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Endometrial Cancer", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "AVZO-021", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avenzo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2023-08-30", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-06-07T13:22:21.326Z", "location_count": 11, "location_summary": "New Haven, Connecticut • Sarasota, Florida • Tampa, Florida + 8 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Mineola", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867251" }, { "nct_id": "NCT00934895", "title": "Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "abraxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 27, "start_date": "2009-07-15", "completion_date": "2015-08-12", "has_results": true, "last_update_posted_date": "2023-09-18", "last_synced_at": "2026-06-07T13:22:21.326Z", "location_count": 3, "location_summary": "Camden, New Jersey • Hamilton, New Jersey • New Brunswick, New Jersey", "locations": [ { "city": "Camden", "state": "New Jersey" }, { "city": "Hamilton", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00934895" }, { "nct_id": "NCT00827567", "title": "Trial of RAD001 in Triple Negative Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "RAD 001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 6, "start_date": "2009-04", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2014-01-13", "last_synced_at": "2026-06-07T13:22:21.326Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00827567" }, { "nct_id": "NCT06224673", "title": "ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2 Low Breast Carcinoma", "Triple Negative Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Hormone Receptor Positive Breast Carcinoma" ], "interventions": [ { "name": "ARX788", "type": "DRUG" }, { "name": "Computed Tomography (CT)", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Amiloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Laura Huppert, MD, BA", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-05-15", "completion_date": "2029-09-30", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-06-07T13:22:21.326Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06224673" }, { "nct_id": "NCT04577963", "title": "A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer", "Endometrial Cancer", "Solid Tumor, Unspecified, Adult", "Colorectal Cancer" ], "interventions": [ { "name": "Fruquintinib", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchmed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2021-08-09", "completion_date": "2024-06-18", "has_results": true, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-06-07T13:22:21.326Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Port Charlotte", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04577963" }, { "nct_id": "NCT05376878", "title": "An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Metastatic Malignant Neoplasm in the Brain" ], "interventions": [ { "name": "Copper Cu 64-DOTA-Trastuzumab", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "DEVICE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DEVICE", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-12-21", "completion_date": "2026-05-26", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-06-07T13:22:21.326Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05376878" }, { "nct_id": "NCT06092892", "title": "IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Axillary Nodal Disease", "Female Breast Cancer", "Axilla; Breast", "Mastectomy; Lymphedema", "Tumor, Breast" ], "interventions": [ { "name": "Breast Surgery (BCS or mastectomy) with TAD/SNB", "type": "PROCEDURE" }, { "name": "Adjuvant Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Alice Chung", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "FEMALE", "summary": "45 Years and older · Female only" }, "enrollment_count": 45, "start_date": "2024-04-07", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-06-07T13:22:21.326Z", "location_count": 3, "location_summary": "Los Angeles, California • Pasadena, California • Tarzana, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Tarzana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06092892" }, { "nct_id": "NCT06369285", "title": "A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone Receptor Positive HER-2 Negative Breast Cancer", "Metastatic Breast Cancer", "Recurrent Breast Cancer" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Endocrine therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-11-19", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-06-07T13:22:21.326Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06369285" }, { "nct_id": "NCT01572727", "title": "A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "BKM120 matching placebo", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 416, "start_date": "2012-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-06-07T13:22:21.326Z", "location_count": 21, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Greenbrae", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01572727" }, { "nct_id": "NCT07619534", "title": "Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Breast Carcinoma", "Cancer of the Breast", "Malignant Neoplasm of Breast" ], "interventions": [ { "name": "Arm 1", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 139, "start_date": "2026-07-01", "completion_date": "2034-07-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-07T13:22:21.326Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07619534" } ] }